

TapImmune, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

URL:	https://marketpublishers.com/r/TE26F587812BEN.html
Date:	November 15, 2017
Pages:	50
Price:	US\$ 499.00
ID:	TE26F587812BEN

TapImmune, Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between TapImmune, Inc. and its competitors. This provides our Clients with a clear understanding of TapImmune, Inc. position in the **Pharmaceuticals and Biotechnology Industry**.

- The report contains detailed information about TapImmune, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for TapImmune, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.
- The TapImmune, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.
- In the part that describes TapImmune, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of TapImmune, Inc. business.

About TapImmune, Inc.

TapImmune Inc., a development stage biotechnology company, focuses on the development and marketing of products specializing in the application of discoveries in cellular and molecular immunology and cancer biology to the development of proprietary therapeutics aimed at the treatment and eradication of cancer and prevention of infectious diseases. The company's technologies are based on an understanding of the function of a protein pump known as 'TAP', which is located within cells and which is essential to the processing of foreign (microbial) or autologous antigens, and subsequent presentation to the immune

system for eradication of the cancer or infected cell.

Products and Technology in Development

The company has developed its TAP Cancer Vaccine at the UBC Biomedical Research Centre under an agreement. This therapeutic cancer vaccine candidate, to be tested in preclinical toxicology studies, would include the patented use of the TAP-1 gene to restore the TAP protein, with the objective being to develop the TAP technology as a therapeutic cancer vaccine that would restore the normal immune recognition of cancer cells. The company has completed small animal pre-clinical animal testing of its TAP Cancer Vaccine to the extent that is required as a prerequisite for further preclinical toxicology analysis and investigational new drug (IND) application to the United States Federal Drug Administration.

Strategic Alliances

The company has entered into a five-year research license and option agreement with Crucell Holland B.V. (Crucell), whereby Crucell granted it a worldwide license for the research use of its packaging cell (PerC6) technology.

The company signed a license agreement with the National Institute of Health (USA) for the use of the Modified Vaccinia Ankara (MVA) virus for the development of vaccines. It would license this technology for the development of prophylactic vaccines against infectious diseases.

Competition

The company's major competitors include CellGenSys Inc., Dendreon Corp., Genzyme Molecular Oncology, and Transgene S.A.

Significant Events

In June 2010, the company has signed a licensing option agreement with Mayo Clinic Rochester for clinical development of a breast cancer vaccine technology.

On August 4, 2010, TapImmune, Inc. announced that the company has signed a research and technology license option agreement with Mayo Clinic Rochester for the development of a smallpox vaccine technology.

The above Company Fundamental Report is a half-ready report and contents are subject to change. It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Table of Content

RESEARCH METHODOLOGY

DISCLAIMER

1. TAPIMMUNE, INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. TAPIMMUNE, INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. TAPIMMUNE, INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. TAPIMMUNE, INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
 - 4.1.1. Income Statement
 - 4.1.2. Balance Sheet
 - 4.1.3. Cash Flow
- 4.2. Financial Ratios
 - 4.2.1. Profitability
 - 4.2.2. Margin Analysis
 - 4.2.3. Asset Turnover
 - 4.2.4. Credit Ratios
 - 4.2.5. Long-Term Solvency
 - 4.2.6. Growth Over Prior Year
 - 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. TAPIMMUNE, INC. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. TapImmune, Inc. Direct Competitors
- 5.2. Comparison of TapImmune, Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of TapImmune, Inc. and Direct Competitors Stock Charts
- 5.4. TapImmune, Inc. Industry Analysis
 - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
 - 5.4.2. TapImmune, Inc. Industry Position Analysis

6. TAPIMMUNE, INC. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. TAPIMMUNE, INC. EXPERTS REVIEW¹

- 7.1. Experts Opinion
- 7.2. Experts Estimates

8. TAPIMMUNE, INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

10. TAPIMMUNE, INC. IFE, EFE, IE MATRICES²

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

11. TAPIMMUNE, INC. PORTER FIVE FORCES ANALYSIS²

12. TAPIMMUNE, INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF TABLES

TapImmune, Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
TapImmune, Inc. Key Executives
Key Executives Biographies¹
Key Executives Compensations¹
TapImmune, Inc. Major Shareholders
TapImmune, Inc. History
TapImmune, Inc. Products
Revenues by Segment
Revenues by Region
TapImmune, Inc. Offices and Representations
TapImmune, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
TapImmune, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
TapImmune, Inc. Capital Market Snapshot
TapImmune, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios

Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
TapImmune, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
TapImmune, Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

LIST OF FIGURES

TapImmune, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
TapImmune, Inc. 1-year Stock Charts
TapImmune, Inc. 5-year Stock Charts
TapImmune, Inc. vs. Main Indexes 1-year Stock Chart
TapImmune, Inc. vs. Direct Competitors 1-year Stock Charts
TapImmune, Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

I would like to order:

Product name: TapImmune, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Product link: <https://marketpublishers.com/r/TE26F587812BEN.html>
Product ID: TE26F587812BEN
Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/TE26F587812BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**